Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Participants in Asia With Early Triple-Negative Breast Cancer An Updated Subgroup Analysis of the KEYNOTE-522 Randomized Clinical Trial

Study limitation reported by the research below: “Full paper text was not provided; summary is based on the title, journal, and DOI metadata only. Specific numeric results (pCR rates, EFS data, sample size for the Asian subgroup) could not be extracted and were not included.”